Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
3.610
+0.020 (0.56%)
At close: Dec 5, 2025, 4:00 PM EST
3.680
+0.070 (1.94%)
After-hours: Dec 5, 2025, 7:56 PM EST
Alaunos Therapeutics Revenue
Alaunos Therapeutics had revenue of $7.00K in the twelve months ending September 30, 2025, up 16.67% year-over-year. In the year 2024, Alaunos Therapeutics had annual revenue of $10.00K with 100.00% growth.
Revenue (ttm)
$7.00K
Revenue Growth
+16.67%
P/S Ratio
1,342.82
Revenue / Employee
$6,000
Employees
1
Market Cap
8.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.00K | 5.00K | 100.00% |
| Dec 31, 2023 | 5.00K | -2.92M | -99.83% |
| Dec 31, 2022 | 2.92M | 2.52M | 634.17% |
| Dec 31, 2021 | 398.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 146.00K | -6.24M | -97.71% |
| Dec 31, 2017 | 6.39M | -472.00K | -6.88% |
| Dec 31, 2016 | 6.86M | 2.53M | 58.38% |
| Dec 31, 2015 | 4.33M | 2.96M | 215.51% |
| Dec 31, 2014 | 1.37M | 573.00K | 71.63% |
| Dec 31, 2013 | 800.00K | - | - |
| Dec 31, 2012 | 800.00K | 133.00K | 19.94% |
| Dec 31, 2011 | 667.00K | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TCRT News
- 5 months ago - Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - GlobeNewsWire
- 7 months ago - PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) - GlobeNewsWire
- 2 years ago - Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - GlobeNewsWire
- 2 years ago - Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS) - Benzinga
- 2 years ago - Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives - GlobeNewsWire
- 2 years ago - Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies - GlobeNewsWire
- 2 years ago - Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
- 2 years ago - Alaunos Therapeutics, Inc. (TCRT) Q1 2023 Earnings Call Transcript - Seeking Alpha